Clinical Trial Update: Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose ibTrutinib and itraconazole for efficacy and safety in chronic graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ibrutinib (low-dose) (ibrutinib)
• Itraconazole (Itraconazole)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Chronic Graft-versus-host-disease | Phase 2 | Status: UNKNOWN